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Ticagrelor (AZD6140) is the ﬁrst reversibly binding oral P2Y12 receptor an-
tagonist that blocks ADP-induced platelet aggregation. Unlike thienopyridines,
which irreversibly bind to the P2Y12 receptor for the lifetime of the platelet,
ticagrelor binds reversibly to the receptor and exhibits rapid onset and off-
set of effect, which closely follow drug exposure levels. Animal models in-
dicate greater separation between antithrombotic effects and bleeding ef-
fects with ticagrelor than with thienopyridines. Unlike the thienopyridines,
ticagrelor does not require metabolic activation. It is quickly absorbed and
exhibits a rapid antiplatelet effect, with higher and more consistent levels of
inhibition of platelet aggregation (IPA) being maintained across the dosing in-
terval than with clopidogrel. IPA levels decline with plasma drug levels after
discontinuation of dosing. In the phase II DISPERSE-2 trial of 990 patients with
non-ST-elevation acute coronary syndromes (ACS), ticagrelor treatment with
90 mg and 180 mg twice daily showed comparable rates of major and minor
bleeding compared with clopidogrel 75 mg while there were numerically fewer
myocardial infarctions. Ticagrelor resulted in greater IPA in clopidogrel-na¨ ıve
patients and produced substantial additional reductions in platelet aggregation
activity in patients pretreated with clopidogrel. Ticagrelor treatment was well
tolerated in DISPERSE-2, and discontinuation rates were comparable to those
observed for clopidogrel. An increased risk of mild to moderate dyspnea and
mostly asymptomatic ventricular pauses were observed in phase II studies. The
mechanisms for these effects are currently being investigated. The efﬁcacy and
safety of ticagrelor are being further evaluated in the phase III PLATO trial, in-
volving approximately 18,000 patients with ACS, including both ST-elevation
and non-ST-elevation ACS.
Introduction
Oral antiplatelet therapy including a platelet P2Y12 re-
ceptor inhibitor is a cornerstone of antithrombotic treat-
ment in patients with acute coronary syndromes (ACS)
with or without ST-segment elevation and in patients un-
dergoing percutaneous coronary intervention (PCI) [1–
4]. However, the thienopyridine clopidogrel, the most
widely used P2Y12 inhibitor, has a number of important
limitations. First, the irreversible inhibition of platelets
(a thienopyridine characteristic) that persists through-
out the lifetime of the platelet may complicate man-
agement in patients who might require surgery and
would therefore be at increased risk of bleeding. Sec-
ond, clopidogrel requires hepatic conversion to an ac-
tive metabolite (a thienopyridine characteristic), result-
ing in delayed onset of effect and posing the potential
for variable interindividual platelet effects associated with
variable metabolism [5–8]. Third, mean levels of inhi-
bition of adenosine diphosphate (ADP)-induced platelet
aggregation observed with clopidogrel are modest and
responses to this agent are variable [9–14], including
hyporesponsiveness that has been associated with in-
creased risk of adverse clinical outcomes [15–25]. These
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drawbacks may be partly overcome with prasugrel, a
new thienopyridine agent that is more efﬁciently me-
tabolized to its active form and whose magnitude and
consistency of platelet ADP inhibition is greater than
clopidogrel [26–28].
Results from the TRITON-TIMI 38 study (Trial to Assess
Improvement in Therapeutic Outcomes by Optimizing
Platelet Inhibition with Prasugrel-Thrombolysis in My-
ocardial Infarction 38) have shown that prasugrel treat-
ment compared with clopidogrel in moderate-to-high-
risk ACS patients scheduled for PCI signiﬁcantly reduced
occurrence of the primary efﬁcacy endpoint of death from
cardiovascular causes, nonfatal myocardial infarction, or
nonfatal stroke (9.9% vs. 12.1%; hazard ratio [HR] 0.81;
95% CI 0.73–0.90). However, the improved clinical ben-
eﬁts were accompanied by a signiﬁcantly increased risk
for non-CABG-related TIMI major bleeding, occurring in
2.4% of patients treated with prasugrel and 1.8% of pa-
tients treated with clopidogrel (HR 1.32; 95% CI 1.03–
1.68) [29].
Ticagrelor (AZD6140), the ﬁrst reversibly binding oral
P2Y12 receptor antagonist, has the potential to address
many of the limitations of thienopyridine therapy. Here,
we review evidence demonstrating that ticagrelor (1) is
not a prodrug and therefore does not require metabolic
activation, has a rapid and reversible concentration-
dependent inhibitory effect on the P2Y12 receptor, and
appears to offer a wider separation between antithrom-
botic effects and bleeding time in preclinical models; (2)
provides greater and more consistent inhibition of ADP-
induced platelet aggregation than clopidogrel without an
increase in major plus minor bleeding in phase II studies;
(3) offers the potential for greater ﬂexibility in the man-
agement of patients at risk for thrombotic events due to
rapid onset and offset of antiplatelet effect; and (4) may
also exert antithrombotic activity beyond platelet inhi-






lopentane-1,2-diol] is a cyclopentyl-triazolo-pyrimidine
(CPTP), a new chemical class of antiplatelet agents
that differs from both thienopyridines and ATP analogs
(Figure 1) [30,31]. Discovery of this class arose from
efforts to identify stable analogs of ATP, the natural
antagonist of the P2Y12 receptor, to be used as a phar-
macologic tool for study of P2Y12 activity (Table 1) [31].
Exploration of structure–activity relationships showed
Figure 1 Chemicalstructureofticagrelor.Adaptedwithpermissionfrom
van Giezen and Humphries [30].
Table 1 Key elements in the medicinal, chemical journey from ATP
through the ATP analog cangrelor to the CPTP ticagrelor
 Introducing afﬁnity-enhancing 5,7-hydrophobic substituents
 Replacing the labile triphosphates group
 Changing the core purine to a triazolopyrimidine, increasing afﬁnity
100-fold
 Finding the ﬁrst nonacidic reversible antagonists
 Introducing the trans-2-phenylcyclopropylamino substituent,
increasing afﬁnity more than 10-fold
 Identifying metabolically stable neutral compounds by modifying the
hydrophobic phenylcyclopropyl group and the hydroxylic side chain
substituent
From Springthorpe et al. [31].
afﬁnity-increasing propertie of substituents in the 2
position of the ATP adenine ring and stability-increasing
properties of β,γ-methylene substitutions in the triphos-
phate. Beginning with the resultant ATP analogs, a drug
development program led to identiﬁcation of several po-
tent selective P2Y12 antagonists, which, due to the short
half-life resulting from retention of the triphosphate
chain, would require intravenous (IV) administration.
One of these compounds, the ATP analog cangrelor
(AR-C69931MX), is being developed as an IV antiplatelet
agent. Subsequent modiﬁcations to these compounds
included elimination of phosphates and changes in the
core purine and sugar moiety, resulting in identiﬁcation
of the ﬁrst selective and stable nonphosphate P2Y12 an-
tagonist AR-C109318XX. Further reﬁnement to improve
oral bioavailability resulted in development of ticagrelor,
the ﬁrst CPTP to be developed clinically.
Preclinical Pharmacology
Binding studies in rh-P2Y12 receptor-transfected CHO-K1
cells indicate that ticagrelor exhibits potent, rapid, and
reversible binding, with a Kd of 10.5 nM, a kon (asso-
ciation constant) of 0.00011/(nM·s), a koff (dissociation
constant) of 0.00087/s, and half-life values of 4 min for
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binding and 14 min for unbinding [32]. The rapid on/off
receptor kinetics of ticagrelor indicate that its inhibitory
effect closely reﬂects levels of drug exposure.
The selectivity of effect for the P2Y12 receptor was
shown in a murine laser-injury model, in which tica-
grelor reduced thrombus formation in P2Y12-positive
mice (+/+) to levels found in P2Y12-deleted mice (−/−),
with no additional suppression of thrombus formation
observed in the latter with ticagrelor treatment [33].
Ticagrelor binds to the P2Y12 receptor at a site dis-
tinct from the ADP-binding site, as initially shown in
studies in which CPTP did not prevent binding of ADP
[34], and appears to inhibit ADP-induced receptor sig-
naling in a noncompetitive manner [35]. In studies
in rh-P2Y12-transfected CHO-K1 cells using a GTPγS
G-protein binding assay, ADP acted as a partial ag-
onist of P2Y12 compared with 2-MeSADP (150-fold
greater potency and 2.5-fold greater binding effective-
ness), a potent P2Y12 agonist that interfered with bind-
ing of both ADP and ticagrelor. Ticagrelor competitively
inhibited 2-MeSADP-induced receptor signaling, displac-
ing the concentration–response curve to the right, and
Figure 2 (A and B) ADP binds to the P2Y12 receptor, resulting in confor-
mational change and G-protein activation. (C) Binding of the clopidogrel
activemetabolitetotheP2Y12receptorisirreversible,renderingtherecep-
tornonfunctionalforthelifeoftheplatelet.(D)Ticagrelorbindsreversibly
to P2Y12 at a site distinct from the ADP-binding site and inhibits ADP sig-
nalingandreceptorconformationalchangeby“locking”thereceptorinan
inactivestate;thereceptorisfunctionalafterdissociationoftheticagrelor
molecule. ADP can still bind at its binding site, and the degree of recep-
tor inhibition (and inhibition of ADP-induced signaling) is dependent on
theconcentrationofticagrelor.AdaptedwithpermissionfromvanGiezen
[36].
noncompetitively inhibited ADP-induced signaling, as in-
dicated by a right-shifting of the concentration–response
curve and by suppression of the ADP-induced signal (re-
duction of Emax). Since ticagrelor does not prevent ADP
binding, it is hypothesized that it acts by inhibiting the
receptor conformational change and G-protein activation
induced by ADP binding, hence “locking” the receptor in
an inactive state and inhibiting ADP signaling (Figure 2)
[36]. Unlike thienopyridines, which bind covalently to
P2Y12, induce conformational change, and render the re-
ceptor permanently inactivated, ticagrelor binding leaves
the receptor intact upon dissociation. Thus, inhibition of
platelet aggregation (IPA) is dependent on the concentra-
tion of drug in plasma available to occupy receptors. Off-
set of inhibitory effect should reﬂect plasma drug levels
with cessation of effect closely following drug adminis-
tration/availability and degree of IPA dropping with de-
clining systemic drug concentrations.
The greater afﬁnity for the P2Y12 receptor and greater
potency in platelet inhibition for ticagrelor than those of
prasugrel were demonstrated in in vitro studies with com-
pound 105, a chemical compound indistinguishable from
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the active metabolite of prasugrel [37]. In a P2Y12 recep-
tor ﬁltration assay, ticagrelor exhibited up to 100 times
the comparator’s afﬁnity for P2Y12 (on measurement of
50% inhibitory concentration, IC50) at shorter incubation
time to 1 min (IC50 of 0.074 ± 0.038 μM for ticagrelor vs.
8.27 ± 2.91 μM for compound 105) and reached equi-
librium within 15 min. In comparison, no equilibrium
was reached with compound 105 over the 2-h measure-
ment period (by IC50 and 125I-285 displacement), indi-
cating slow receptor kinetics for the latter. Ticagrelor ex-
hibited 48-fold greater potency in inhibiting 2-MeSADP
receptor activation in the GTPγS binding assay compared
with compound 105 (IC50 of 0.059 ± 0.03 μM vs. 2.84 ±
0.83 μM) and 63-fold greater potency in inhibiting
platelet aggregation in an ADP-induced washed-platelet
aggregation assay (IC50 of 0.005 ± 0.004 μM vs. 0.313 ±
0.12 μM). These ﬁndings support the rapid onset of an-
tiplatelet effect and high levels of platelet inhibition ob-
served with ticagrelor in clinical evaluation.
The binding characteristics of ticagrelor appear to be as-
sociated with a wider separation between antithrombotic
effects and bleeding effects than that seen with thienopy-
ridines, as shown in rat and dog models of hemostasis and
thrombosis [30,38]. In both the dog cyclic ﬂow reduction
model (modiﬁed Folts model) and a rat model using FeCl3
intimal injury, IV ticagrelor, clopidogrel, and compound
072, a chemical compound indistinguishable from pra-
sugrel, dose-dependently inhibited arterial thrombus for-
mation. Results in both models suggested that ticagrelor
was able to achieve higher levels of antithrombotic effects
than thienopyridines, without an equivalent increase in
associated bleeding time (Figure 3, Table 2). In the rat
model, the separation between antithrombotic and bleed-
ing effects was calculated as the ratio of the dose resulting
in a 3.0-fold increase in tail bleeding time (EDBT:3.0)t ot h e
dose restoring blood ﬂow to 50% of control values (50%
effective dose, ED50). This ratio (EDBT:3.0/ED50)w a s9 . 7
with ticagrelor, compared with 2.0 with clopidogrel and
1.4 with compound 072. In dogs, the ratio for the dose
resulting in a 3.5-fold increase in tongue bleeding time
to the ED50 for blood ﬂow (EDBT:3.5/ED50)w a s>5.2 with
ticagrelor (bleeding time was not increased by 3.5-fold at
the highest ticagrelor dose; see Figure 3) compared with
2.3 with clopidogrel and 4.3 with compound 072.
Potential Effect on ADP-Induced
Vasoconstriction
Preclinical studies also suggest that reversible P2Y12 inhi-
bition may be associated with beneﬁcial effects on P2Y12-
mediated vasoconstriction, effects that may permit re-
duction in thrombogenic vasospasm or reduce deﬁcits in
myocardial perfusion after thrombosis. P2Y12 receptors
are present in vascular smooth muscle cells in concen-
trations greater than other ADP receptors – for example,
P2Y1 and P2Y13 – and are active in stimulating vessel
contraction. In studies in arterial segments from pa-
tients undergoing coronary bypass, P2Y12-mediated vaso-
constriction was demonstrated using 2-MeSADP-induced
contraction of submaximally precontracted vessels [39].
This contraction was blocked by a selective reversible
P2Y12 antagonist (AR-C67085) and not blocked by a
selective P2Y1 antagonist. No inhibition of contraction
was observed in vessels from patients pretreated with
clopidogrel. It is hypothesized that the short half-life
and physicochemical properties of thienopyridine active
metabolites prevent these drugs from entering the vascu-
lar wall and that systemically available drugs such as tica-
grelor may, in contrast, be available to interact with these
receptors.
The ability of ticagrelor to inhibit ADP-induced
contractions in vascular smooth muscle was shown
in an ex vivo study in denuded mouse aortic rings.
In these studies, 2-MeSADP-induced contractions
were 59% of maximal values (obtained with
potassium-rich buffer) in mice that were not pre-
treated and 64% in mice pretreated with clopidogrel
50 mg/kg [40]; the addition of ticagrelor 10 μM
to the vessel segment in tissue bath resulted in signiﬁ-
cant inhibition of ADP-induced contraction, to 33% of
maximal in the untreated group and 32% of maximal
in the clopidogrel-pretreated group. These ﬁndings
suggest that ticagrelor could modulate vasoreactivity
mediated by locally increased levels of ADP in vivo;
pretreatment with clopidogrel does not appear to inhibit
ADP-induced contractions. The potential effects of such
inhibition were shown in a study in a dog thrombosis
model, in which treatment with the selective P2Y12
antagonist AR-C69931MX (4 μg/(kg·min)) resulted in
decreased reocclusion and cyclic ﬂow variation and
improved myocardial ﬂow compared with placebo in
animals receiving tissue-type plasminogen activator
and heparin after thrombus formation [41]. Another
study using the same thrombosis model in dogs com-
pared adjunctive infusion of ticagrelor (75 μg/kg IV
bolus, followed by 10 μg/(kg·min) IV infusion over 2
h) with clopidogrel (10 mg/kg IV bolus over 5 min)
and placebo, on top of ﬁbrinolytic therapy (t-PA +
heparin). In this study, both clopidogrel and ticagrelor
treatment resulted in complete blockade of ADP-induced
platelet activation, aggregation, and recruitment, and
prevented platelet-mediated thrombosis. However, de-
spite similar antiplatelet effects, animals treated with
ticagrelor had signiﬁcantly lower rates of reocclusion
(0% for ticagrelor vs. 30% for clopidogrel), less cyclic
ﬂow variation (0% vs. 30%), longer reﬂow duration
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Figure 3 Antithromboticeffectsandbleedingtimewith(A)ticagrelor,(B)
clopidogrel, and (C) compound 072, a chemical compound indistinguish-
able from prasugrel, in animal models. Left panels: Percent of thrombus
size inhibition, percent of arterial blood ﬂow, and n-fold increase in bleed-
ingtimeversuscontrolaccordingtodoseofeachdruginanesthetizedrat
model.Dataaremean±standarderrorofthemean(SEM);n=4–6.Right
panels: Percent of arterial blood ﬂow, percent of IPA ex vivo, and n-fold
increaseinbloodlossandbleedingtimeversuscontrolaccordingtodose
of each drug in anesthetized dogs. Data are mean ± SEM; n = 6. Adapted
with permission from van Giezen et al. [38].
(120 ± 0.0 min vs. 96.9 ± 38.9 min), and greater
reductions in infarct sizes (ﬁnal size of 6.31 ± 2.86 cm2
vs. 14.63 ± 4.29 cm2) [42]. Taken together, these data
suggest that the systemic presence of reversible inhibitors
may exert additional beneﬁt, for example, via inhibition
of nonplatelet P2Y12 receptors.
Ticagrelor may confer additional beneﬁts in patients
with ACS by inhibiting uptake of adenosine by human
erythrocytes. In suspensions of washed human erythro-
cytes, ticagrelor dose-dependently inhibited adenosine
uptake by erythrocytes with a pIC50 of 7.0 ± 0.1 (n = 5),
which was 10-fold less potent than dipyridamole [43].
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Table 2 Effects of ticagrelor, clopidogrel, and compound 072, a chemical compound indistinguishable from prasugrel, in rat and dog models of arterial
thrombosis and hemostasis
Ticagrelor Clopidogrel Compound 072
Rat model
Blood ﬂow (ED50)3 . 1 μg/(kg·min) 10 mg/kg 1.1 mg/kg
Bleeding time (EDBT:3.0)3 0 μg/(kg·min) 20 mg/kg 1.5 mg/kg
EDBT:3.0/ED50 9.7 2.0 1.4
Inhibition of thrombus size (ED50)4 . 5 μg/(kg·min) 17 mg/kg 1.0 mg/kg
Dog model
Blood ﬂow (ED50)1 . 9 0 μg/(kg·min) 1.68 mg/kg 0.3 mg/kg
Bleeding time (EDBT:3.5) >10 μg/(kg·min) 3.9 mg/kg 1.3 mg/kg
EDBT:3.5/ED50 >5.2 2.3 4.3
Ex vivo platelet aggregation (ED50)1 . 0 2 μg/(kg·min) 0.62 mg/kg 0.2 mg/kg
F r o mv a nG i e z e ne ta l .[ 3 8 ] .
ED50, dose yielding 50% antithrombotic effect; EDBT, dose yielding n-fold increase in bleeding time versus control.
Data are combinedfor alldoses.Therapeutic windowdeﬁnedas the ratio ofthe dose inducinga 3.0-fold (rats)or 3.5-fold (dogs) increasein bleeding time
to the dose inducing a 50% antithrombotic effect as measured via restoration of blood ﬂow.
Adenosine is one of the mediators of the reactive hyper-
emia response to temporary coronary artery occlusion.
In vivo data from a canine model of coronary blood ﬂow
regulation conﬁrmed that both ticagrelor (n = 8) and
dipyridamole (n = 8) dose-dependently augment the hy-
peremic response to temporary occlusion of direct intra-
coronary adenosine infusion, without affecting measured
blood ﬂow in the circumﬂex artery. In vehicle-treated an-
imals, infusion of adenosine 15 μg/min or 30 μg/min re-
sulted in blood ﬂow in the left anterior descending artery
126.8 or 227.3% of baseline, respectively. Systemic ad-
ministration of ticagrelor 30 or 100 μg/(kg·min) resulted
in blood ﬂow 114 ± 10% or 150 ± 19% of baseline, re-
spectively, following infusion of adenosine 15 μg/min,
and 109 ± 10% or 140 ± 13% of baseline, respectively,
following infusion of adenosine 30 μg/min. Administra-
tion of dipyridamole 0.17 or 0.50 μg/(kg·min) resulted in
blood ﬂow 160 ± 2% or 193 ± 17% of baseline following
adenosine 15 μg/min, and 136 ± 17% or 153 ± 30% fol-
lowing adenosine 30 μg/min. These results conﬁrm that
both ticagrelor and dipyridamole augment the adenosine-
induced increase in coronary blood ﬂow in this model
and suggest that ticagrelor may deliver additional beneﬁts
to patients with ACS by enhancing adenosine-induced
coronary blood ﬂow increases. Translation of these results




Ticagrelor is rapidly absorbed following oral administra-
tion. It is metabolized primarily via cytochrome P450
3A enzymes and has one known active metabolite, AR-
C124910XX, that is present in blood at approximately
one-third of the concentration of the parent drug [30].
Although this metabolite has potency in inhibiting the
P2Y12 receptor equivalent to that of the parent com-
pound, metabolic activation is not a requirement for
IPA to occur. The pharmacokinetics of ticagrelor and its
metabolite are predictable, with plasma concentrations
being dose-proportional after initial dosing and stable at
steady state [44].
In six subjects receiving a single oral dose of 14C-
ticagrelor 200 mg suspension, the average total recov-
ery of radioactive dose was 84.3%, consisting of 26.5%
in urine and 57.8% in feces [44]. The mean radioac-
tivity plasma/blood ratio was 1.69, indicating that most
radioactivity is restricted to the plasma space. Ticagrelor
and its active metabolite, AR-C124910XX, constituted
the major components identiﬁed in feces, plasma, and
less than 1% of components in urine. The primary
components in urine were the inactive metabolite AR-
C133913XX and its glucuronide conjugate. These ﬁnd-
ings indicate that ticagrelor and AR-C124910XX are ex-
tensively metabolized and suggest that renal impairment
may have little effect on systemic exposure to the active
compounds. No extensive penetration or binding to ery-
throcytes was observed for either ticagrelor or the active
metabolite.
In single-dose pharmacokinetic/pharmacodynamic
studies [46,47], subjects received oral ticagrelor in doses
of 0.1–100 mg, 30–400 mg, or 900–1260 mg. Absorption
was rapid (median tmax 1.5–3 h for both ticagrelor and
its active metabolite), area under the concentration–time
curve (AUC) and Cmax increased in an apparently dose-
proportional manner, and t1/2 was 7.1–12 h for ticagrelor
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Table 3 Mean IPA (20 μM ADP, ﬁnal extent) over 24 h at speciﬁed testing times in healthy subjects receiving ticagrelor 50–300 mg bid, clopidogrel
300-mg loading dose or 75 mg/day, or placebo
n Inhibition (%), mean (range)
Treatment group 4 h 8 h 12 h 24 h
Ticagrelor
50 mg bid, day 1 14 92 (55–100) 82 (19–100) 66 (0–100) 88 (45–100)
50 mg bid, day 5 14 95 (62–100) 90 (27–100) 87 (13–100) 79 (3–100)
100 mg bid, day 5 13 97 (72–100) 95 (63–100) 93 (43–100) 93 (65–100)
200 mg bid, day 5 13 98 (85–100) 98 (89–100) 96 (79–100) 97 (76–100)
300 mg bid, day 5 7 100 (100–100) 100 (100–100) 99 (97–100) 100 (100–100)
Clopidogrel
300-mg loading dose, day 1 14 67 (0–100) 52 (0–98) 57 (0–100) 56 (0–100)
75 mg, day 14 14 90 (35–100) 82 (14–100) 83 (30–100) 77 (11–100)
Placebo 39 7 (0–25) 8 (0–38) 8 (0–48) 5 (0–28)
From Peters et al. [48], Butler et al. [44].
Day refers to day within treatment group, not day within study.
(8.5–10.1 h for the active metabolite). At 2 h postdose,
IPA (20 μM ADP) measured by optical aggregometry
for ﬁnal extent was 88–95% at doses of 100–400 mg; at
these doses, IPA plateaued at 88–100% and decreased to
74–89% at 12 h. No safety/tolerability issues occurred at
doses up to 900 mg, with dose-limiting gastrointestinal
adverse events such as nausea, vomiting, and abdominal
pain occurring at 1260 mg.
In multiple-dose studies in healthy volunteers, subjects
(n = 48) received ticagrelor 30–600 mg once daily (qd)
or 50–300 mg twice daily (bid) for 16–20 days or clopido-
grel at a 300-mg loading dose plus 75 mg/day for 14 days
[44,48]. Plasma levels of ticagrelor peaked 1.5–3 h af-
ter dosing and reached steady state after 2–3 days. Mean
t1/2 ranged from 6.2 to 13.1 h with qd dosing and from
6.6 to 9.1 h with bid dosing, and Cmax and AUC increased
in a dose-proportional manner. IPA (20 μM ADP, ﬁnal
extent) closely followed ticagrelor plasma levels and was
thus dose- and time-dependent. IPA was higher and less
variable at ticagrelor doses of more than 100 mg bid and
more than 300 mg qd than with clopidogrel 75 mg. At
bid dosing of 100 mg, the proﬁle of which is similar to
the 90 mg formulation taken twice daily, or higher, IPA
was nearly complete (>90%) over 24 h (Table 3). Bleed-
ing time was modestly prolonged compared with placebo;
from a median baseline value of 165 seconds, a 1.1- to
3.3-fold increase in bleeding time was seen after adminis-
tration of ticagrelor versus a 1.1- to 1.2-fold increase with
placebo. Treatment was well tolerated with no serious or
dose-related adverse events.
A study in which healthy subjects were coadministered
ticagrelor 50 or 200 mg bid and aspirin 300 mg qd for
10 days showed no effect of aspirin on ticagrelor pharma-
cokinetics, ADP-induced platelet aggregation response, or
rate or extent of IPA [49]. However, aspirin increased the
inhibition of collagen-induced platelet aggregation (e.g.,
from 20% [range 0–43%] with ticagrelor 200 mg alone
to 76% [range 55–92%]), reﬂecting the combined an-




Phase II studies have shown that ticagrelor treatment pro-
duces rapid, high, and consistent IPA, with degree of IPA
reﬂecting plasma drug levels, with no increase in ma-
jor plus minor or major bleeding rates compared with
clopidogrel. Ticagrelor treatment was generally well tol-
erated in these studies. Safety ﬁndings included an appar-
ent dose-related incidence of dyspnea, a greater incidence
of mostly asymptomatic ventricular pauses in ticagrelor
patients, and a mild increase in uric acid levels.
DISPERSE: Patients with Stable
Atherosclerosis
In the DISPERSE trial [50], 200 patients with stable
atherosclerotic disease were randomized to ticagrelor
50 mg (n = 41), 100 mg (n = 39), or 200 mg (n =
37) bid or to 400 mg qd (n = 46) or to clopidogrel at
the standard maintenance dose of 75 mg/day (n = 37)
for 28 days along with aspirin (75–100 mg/day). The
main pharmacodynamic measure was inhibition of ADP-
induced platelet aggregation (20 μM ADP) measured by
optical aggregometry, and the primary tolerability mea-
sure was the incidence of adverse events.
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Table 4 Mean (coefﬁcient of variation percentage) pharmacokinetic values for ticagrelor and active metabolite in patients in DISPERSE
50 mg bid 100 mg bid 200 mg bid 400 mg qd
Day 1 Day 28 Day 1 Day 28 Day 1 Day 28 Day 1 Day 28
(n = 41) (n = 38) (n = 39) (n = 33) (n = 37) (n = 35) (n = 46) (n = 39)
Ticagrelor
tmax (h) 3.66 (41) 3.33 (56) 3.05 (50) 2.52 (55) 3.09 (57) 2.74 (82) 2.03 (63) 2.12 (71)
Cmax (ng/mL) 287 (70) 387 (57) 594 (55) 798 (59) 1224 (35) 2200 (41) 3374 (41) 3827 (42)
AUC (ng·h/mL) 1640 (50) 2688 (56) 3648 (56) 5337 (45) 7581 (35) 15,104 (39) NA 31,338 (53)
CL/F (L/h) NA 23.7 (48) NA 22.6 (44) NA 15.3 (39) NA 15.6 (39)
AR-C124910XX
tmax (h) 4.23 (33) 3.25 (61) 3.69 (32) 3.22 (45) 3.71 (43) 3.16 (69) 3.17 (41) 3.26 (53)
Cmax (ng/mL) 73 (109) 118 (61) 135 (50) 239 (38) 271 (39) 660 (51) 595 (32) 860 (47)
AUC (ng·h/mL) 418 (58) 906 (48) 899 (46) 1881 (32) 1753 (32) 5268 (41) – 10,466 (45)
From Husted et al. [50].
CL/F, total plasma oral clearance.
Pharmacokinetics
Pharmacokinetic parameters are shown in Table 4 [50].
Drug and metabolite concentrations increased in a lin-
ear and dose-proportional manner and were stable
and predictable at steady state (reached by day 14).
At day 28, pharmacokinetics were slightly more than
dose-proportional in the 200 mg bid and 400 mg qd
groups (dose-normalized AUCs approximately 50% more
than dose proportional with correspondingly lower total
plasma oral clearance than seen with lower doses). Cmax
and AUC values did not vary by gender or age 65 years
or less or more than 65 years for ticagrelor.
Inhibition of Platelet Aggregation
Ticagrelor exhibited peak IPA (ﬁnal extent) at 2- to 4-h
postdose on day 1 and at steady state (day 28), whereas
clopidogrel minimally inhibited aggregation on day 1
(<20% at all time points). The 100-mg and 200-mg bid
and 400-mg qd doses produced nearly complete IPA on
day 1 and at day 28 (∼85–95%, Figure 4A), with the
magnitude of inhibition at these doses being greater than
that with the 50-mg bid dose of ticagrelor or with clopido-
grel and with less variability in IPA (Figure 4B) [50]. On-
set of maximum IPA effect was rapid and corresponded
with plasma concentrations. Reversibility of effect was in-
dicated by declining IPA values over the 24 h following
the last dose (day 28). At 24 h after the last dose of study
drug, ticagrelor at doses of 100 mg and higher maintained
higher levels of IPA than clopidogrel.
Safety/Tolerability
Ticagrelor treatment was well tolerated. Bleeding was
the most frequently observed adverse event (Table 5);
all bleeding events, deﬁned according to a set of deﬁni-
tions modiﬁed from Clopidogrel in Unstable angina to
prevent Recurrent Events (CURE) criteria, were minor
and considered mild to moderate in severity, except for
one major bleeding event in a patient receiving ticagrelor
400 mg qd. The incidence of bleeding appeared to in-
crease with increasing ticagrelor dose. Dyspnea was also
observed in ticagrelor patients, which appeared to be
transient and dose-related. Of 29 cases of dyspnea (23
in patients treated with ticagrelor), 21 were considered
mild and 8 moderate, and none was associated with con-
gestive heart failure or bronchospasm. Overall, dyspnea
l a s t e df o ru pt o4hi n6o ft h ep a t i e n t s ,f o r1w e e ko rl e s s
in 5 more patients, for up to 2 weeks in 4 more patients,
for up to 3 weeks in 3 more patients, and for more than
3 weeks in 5 more patients. Other adverse events occur-




In DISPERSE-2, 990 patients (984 in safety cohort) with
non-ST-elevation ACS receiving aspirin and standard
therapy for ACS were randomized to ticagrelor 90 mg
bid (n = 334), with a proﬁle similar to ticagrelor 100
mg bid studied in DISPERSE, or 180 mg (n = 323) bid
or to clopidogrel (n = 327) at a 300-mg loading dose
followed by 75 mg/day for up to 12 weeks [51]. Pa-
tients in the ticagrelor group were also randomized to
a loading dose of 270 mg or no loading dose, and pa-
tients undergoing PCI within 48 h of randomization could
receive an additional 300 mg of clopidogrel or match-
ing placebo [52]; patients already receiving clopidogrel at
study entry received clopidogrel 75 mg if randomized to
the clopidogrel group. Across all treatment groups, 66%
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Figure 4 (A)M e a nI P A( 2 0μM ADP, ﬁnal extent) in patients in DISPERSE
receiving ticagrelor 50, 100, or 200 mg bid or 400 mg qd or clopidogrel
75 qd on day 1, day 14, and day 28. ∗No second dose of ticagrelor was
given on day 28. Error bars indicate standard deviation, shown only for
IPA sample space. (B) Median (line in box), 25–75% percentile (box), and
10–90% percentile (whiskers) IPA predose and 4-h postdose on day 14
(ﬁnal extent). Adapted with permission from Husted et al. [50].
of patients underwent diagnostic coronary angiography,
43% had PCI, and 9% underwent coronary artery bypass
grafting (CABG). The primary outcome measure was the
Kaplan–Meier rate of major plus minor bleeding through
4 weeks.
Bleeding
The Kaplan–Meier rate of protocol-deﬁned major and
minor bleeding (modiﬁed from CURE criteria; Table 6)
did not differ signiﬁcantly among treatment groups at
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Table 5 Adverse events occurring in ≥10% in any treatment group in patients in DISPERSE
Number (%)
Ticagrelor Clopidogrel
50 mg bid 100 mg bid 200 mg bid 400 mg qd 75 mg qd
(n = 41) (n = 39) (n = 37) (n = 46) (n = 37)
Major bleeding events∗ 0 (0) 0 (0) 0 (0) 1 (2) 0 (0)
Minor bleeding events∗ 12 (29) 17 (44) 19 (51) 22 (48) 12 (32)
Venipuncture-site bruise 1 (2) 0 (0) 1 (3) 2 (4) 4 (11)
Epistaxis 1 (2) 4 (10) 4 (11) 8 (17) 2 (5)
Contusion 5 (12) 9 (23) 9 (24) 12 (26) 8 (22)
Red blood cells in urine 3 (7) 0 (0) 4 (11) 0 (0) 1 (3)
Dyspnea 4 (10) 4 (10) 6 (16) 9 (20) 0 (0)
Dizziness 4 (10) 2 (5) 1 (3) 4 (9) 1 (3)
Headache 0 (0) 5 (13) 1 (3) 1 (2) 3 (8)
From Husted et al. [50].
∗A major bleeding event was deﬁned as one that occurred in a critical site, was clinically overt and led to the transfusion of ≥2 units of packed red cells
or whole blood, was clinically overt and associated with a fall in hemoglobin ≥20 g/L, or was fatal; all other bleeding events were classiﬁed as minor.
Table 6 Bleeding deﬁnitions in DISPERSE-2 (modiﬁed from CURE deﬁnitions)
Term Associated with a ↓ Transfusion of whole
in hemoglobin blood or PRBCs for bleeding
Major bleed—fatal/life Fatal or intracranial or intrapericardial with cardiac >50 g/L (3.1 mmol/L) ≥4 units
threatening tamponade or leading to hypovolemic shock or severe
hypotension requiring pressors or surgery
Major bleed—other Signiﬁcantly disabling (e.g., intraocular 30–50 g/L (1.9–3.1 mmol/L) 2–3 units
with permanent vision loss)
Minor bleed Requires medical intervention (e.g., epistaxis requiring 1 unit
visit to medical facility for packing)
Minimal bleed All others not requiring intervention or treatment
(e.g., bruising, bleeding gums, and oozing from injection site)
From Cannon et al. [51].
PRBCs, packed red blood cells
4 weeks, with rates of 8.1% in the clopidogrel group ver-
sus 9.8% in the ticagrelor 90 mg group and 8.0% in the
ticagrelor 180 mg group (Table 7), with no signiﬁcant dif-
ference among groups in rates of major bleeding [51].
Similarly, no signiﬁcant differences were observed for to-
tal bleeding at week 12, with Kaplan–Meier event rates
of 9.9% with clopidogrel versus 10.9% with ticagrelor
90 mg bid and 11.4% with 180 mg bid. Through week 12,
there was a signiﬁcant increase in minor bleeding at the
higher ticagrelor dose. The actual incidence of major and
minor bleeding (which differs from Kaplan–Meier rates
due to differences in follow-up duration among patients)
is shown in Figure 5A. The rate of major and minor bleed-
ing within 48 h of randomization was higher in ticagrelor
patients receiving a loading dose than in those not receiv-
ing a loading dose (Figure 5B).
Analysis of bleeding rates in patients undergoing CABG
suggested the potential for clinical beneﬁt of reversibility
of the effect of ticagrelor in the setting of invasive
intervention [51]. Among 84 patients undergoing CABG,
Table 7 Number of bleeding events and Kaplan–Meier event rate in
DISPERSE-2
Number of events (event rate)
[P-value vs. clopidogrel]
Clopidogrel Ticagrelor Ticagrelor
75 mg qd 90 mg bid 180 mg bid
(n = 327) (n = 334) (n = 323)
Through week 4
Total 26 (8.1) 32 (9.8) [0.43] 25 (8.0) [0.96]
Major 22 (6.9) 23 (7.1) [0.91] 16 (5.1) [0.35]
Fatal/life threatening 14 (4.4) 11 (3.4) [0.53] 10 (3.2) [0.44]
Other 8 (2.5) 12 (3.7) [0.38] 6 (1.9) [0.61]
Minor 4 (1.3) 9 (2.7) [0.18] 12 (3.8) [0.0504]
Through week 12
Total 30 (9.9) 34 (10.9) [0.62] 33 (11.4) [0.72]
Major 26 (8.7) 26 (8.6) [0.96] 20 (6.3) [0.32]
Fatal/life threatening 16 (5.4) 13 (4.5) [0.55] 14 (4.3) [0.61]
Other 10 (3.3) 13 (4.2) [0.54] 6 (1.9) [0.34]
Minor 4 (1.3) 9 (2.7) [0.18] 16 (6.1) [0.01]
From Cannon et al. [51].
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Figure 5 (A)Totalbleedingratesthroughweek4(left)andoverall(right)inDISPERSE-2.(B)Bleedingrateswithin48hofrandomization. ∗Minorbleeding
without major bleeding; †loading dose. Adapted with permission from Cannon et al. [51].
median times to surgery from the last dose of study drug
were 96 h among clopidogrel patients, 55 h among tica-
grelor 90 mg bid patients, and 60 h among ticagrelor
180 mg bid patients. In patients undergoing CABG at
1–5 days after the last dose, major bleeding occurred in
36% (10 of 28) patients receiving ticagrelor, compared
with 64% (9 of 14) receiving clopidogrel. Major bleeding
occurred in 1 (50%) of 2 clopidogrel patients and 5 (50%)
of 10 ticagrelor patients undergoing CABG within 1 day
and in 6 (60%) of 10 clopidogrel patients and 10 (50%)
of 20 ticagrelor patients undergoing CABG at more than
5d a y s .
IPA
A pharmacodynamics substudy was performed in 45
clopidogrel-na¨ ıve patients and 44 clopidogrel-pretreated
patients [52]. Among patients who had not received
clopidogrel pretreatment, ticagrelor patients (n = 18
receiving 90 mg bid, n = 9 with loading dose; n = 13
receiving 180 mg bid, n = 6 with loading dose) had sig-
niﬁcantly greater IPA (ﬁnal extent; 20 μM ADP) than
clopidogrel patients (n = 14, all with loading dose) on
day 1 (Figure 6A) [52]. IPA in ticagrelor-treated patients
remained stable at 4 weeks and higher than that observed
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Figure 6 (A)M e a nI P A( 2 0μM ADP, ﬁnal extent) after ﬁrst dose of tica-
grelor 90 mg (n = 9) or 180 mg (n = 7) or 270-mg loading dose (n =
15) or of clopidogrel 300-mg loading dose (n = 14) in clopidogrel-na¨ ıve
patients in DISPERSE-2. (B) IPA after 4 weeks of treatment and at 24 h af-
ter the end of treatment in clopidogrel-na¨ ıve patients receiving ticagrelor
90 mg bid (n = 15) or 180 mg bid (n = 10) or clopidogrel 75 mg/day
(n=10).(C)Changeinpercentofplateletaggregationamongclopidogrel-
pretreated patients receiving ﬁrst dose of ticagrelor 90 mg (n = 9) or
180 mg (n = 7) or 270-mg loading dose (n = 16) or clopidogrel 75 mg
(n=12).Errorbarsindicatestandarddeviation,shownonlyforIPAsample
space. ∗P <0.05 for ticagrelor versus clopidogrel. Adapted with permis-
sion from Storey et al. [52].
Table 8 Adverse events in DISPERSE-2
Number (%) of patients [P-value vs. clopidogrel]
Clopidogrel Ticagrelor Ticagrelor
75 mg qd 90 mg bid 180 mg bid
(n = 327) (n = 334) (n = 323)
Dyspnea 21 (6.4) 35 (10.5) [0.07] 51 (15.8) [<0.0002]
Chest pain 29 (8.9) 25 (7.5) [0.57] 24 (7.4) [0.57]
Headache 28 (8.6) 32 (9.6) [0.69] 21 (6.5) [0.37]
Nausea 11 (3.4) 22 (6.6) [0.07] 21 (6.5) [0.07]
Dyspepsia 9 (2.8) 16 (4.8) [0.22] 10 (3.1) [0.82]
Insomnia 9 (2.8) 18 (5.4) [0.12] 15 (4.6) [0.22]
Diarrhea 11 (3.4) 10 (3.0) [0.83] 24 (7.4) [0.02]
Hypotension 2 (0.6) 4 (1.2) [0.004] 12 (3.7) [0.01]
Dizziness 10 (3.1) 14 (4.2) [0.53] 11 (3.4) [0.83]
Syncope 2 (0.6) 4 (1.2) [0.69] 5 (1.5) [0.28]
Rash 2 (0.6) 3 (0.9) [1.00] 6 (1.9) [0.17]
From Cannon et al. [51].
Theratesarecrudeincidencesofnumberofpatientswithreportedevents
divided by the total number of patients in the safety cohort.
in clopidogrel-treated patients (Figure 6B). Among pa-
tients receiving clopidogrel prior to study treatment, the
mean level of platelet aggregation at baseline in those re-
ceiving study clopidogrel 75 mg/day was 38% and did
not change signiﬁcantly (36%) at 4-h postdose testing
(Figure 6C). In contrast, each of the ticagrelor doses pro-
duced a signiﬁcant and substantial further reduction in
platelet aggregation irrespective of baseline aggregation
response (Figure 6C). Overall, ticagrelor treatment re-
duced residual platelet aggregation from 62.7 to 7.4% in
those clopidogrel-pretreated patients in the highest ter-
tile of baseline aggregation response and from 19.3 to
2.2% in those in the lowest tertile of baseline aggregation
response.
Pharmacokinetics
In a substudy in patients receiving ticagrelor 90, 180, or
270 mg (along with aspirin), mean plasma levels of tica-
grelor were highest at the 2-h measurement after dosing
and those of AR-C124910XX peaked 2–4 h after dosing
and were one-ﬁfth to one-half as high as ticagrelor [52].
Safety/Tolerability
Adverse events are shown in Table 8 [51]. Dyspnea ap-
peared to be dose-related in ticagrelor patients, with a
signiﬁcantly greater frequency in the higher-dose group
than in the clopidogrel group. Among all patients report-
ing dyspnea, 27% had resolution within 24 h and 48%
(overall 2% of clopidogrel patients and 6% of each tica-
grelor group) had symptoms lasting more than 15 days.
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As in DISPERSE, dyspnea episodes were mild or mod-
erate, were frequently self-limiting, and infrequently led
to drug discontinuation. There were no reported cases of
ﬂuid retention, congestive heart failure, or bronchospasm
in ticagrelor patients reporting dyspnea, suggesting that
the symptom is not related to heart failure.
Hypotension was also more common in ticagrelor
groups, occurring in 1.2% of ticagrelor 90 mg bid pa-
tients: 3.7% of ticagrelor 180 mg bid patients and 0.6%
of clopidogrel 75 mg qd patients. Overall discontinua-
tion rates were low and similar between groups: 6% of
ticagrelor 90 mg bid patients; 7% of patients receiving
180 mg bid; and 6% of patients receiving clopidogrel
75 mg qd. Analysis of continuous ECG monitoring dur-
ing the ﬁrst 4–7 days of treatment in 885 patients in-
dicated that there was no signiﬁcant difference among
groups in rates of ventricular tachycardias. However, a
post hoc analysis showed a greater frequency of mostly
asymptomatic ventricular pauses persisting for more than
2.5 seconds among ticagrelor patients, with rates of 4.3%
among clopidogrel patients, 5.5% (P = 0.58) among tica-
grelor 90 mg bid patients, and 9.9% (P = 0.014) among
ticagrelor 180 mg bid patients. The proportions of patients
with more than three episodes were 0.3, 2.0 (P = 0.12),
and 4.9% (P <0.001), respectively, and the proportions
of those with at least one episode of more than 5 seconds
were 0.3, 1.6 (P = 0.22), and 2.1% (P = 0.06). How-
ever, the observed pauses did not lead to discontinuation
of study drug and were not associated with clinical symp-
toms such as dizziness or syncope.
The mechanisms for dyspnea and ventricular pauses
are unknown and currently being investigated. Although
ticagrelor is not an ATP or adenosine analog, it is possible
that it affects adenosine metabolism, as is the case with
a number of agents that affect cellular adenosine levels
by interfering with adenosine degradation and reuptake.
Such an effect could account for the increased incidence
of ventricular pauses and dyspnea [51].
Table 9 PLATO bleeding deﬁnitions∗ (modiﬁed from CURE deﬁnitions)
Term Associated with Transfusion of whole blood
a ↓ in hemoglobin or PRBCs for bleeding
Major bleed—life Fatal or intracranial or intrapericardial with cardiac >50 g/L (3.1 mmol/L) ≥4 units
threatening tamponade or hypovolemic shock or severe
hypotension requiring pressors or surgery
Major bleed—other Signiﬁcantly disabling (e.g., intraocular with permanent vision loss) 30–50 g/L (1.9–3.1 mmol/L) 2–3 units
Minor bleed Requires medical intervention to stop or treat bleeding
Minimal bleed All others not requiring intervention or treatment
From James et al. [53].
PRBCs, packed red blood cells.
∗If the bleeding event fulﬁlls criteria in more than one category, the event will be assigned to the most severe category.
Cardiovascular Events
There were numerically fewer myocardial infarctions
over 12 weeks with ticagrelor treatment, with Kaplan–
Meier event rates of 5.6% in the clopidogrel group versus
3.8% in the ticagrelor 90 mg bid group and 2.5% in the
ticagrelor 180 mg bid group [51].
Phase III PLATO Trial
PLATelet Inhibition and Patient Outcomes (PLATO) is an
international, randomized, double-blind, double-dummy
phase III trial examining the safety and efﬁcacy of
ticagrelor compared with clopidogrel in approximately
18,000 patients with either non-ST-elevation ACS or ST-
elevation ACS [53]. This trial is designed to test the hy-
pothesis that ticagrelor compared with clopidogrel on a
background of aspirin will result in a lower risk of recur-
rent ischemic events in a broad patient population with
ACS in a setting designed to reﬂect current and evolving
medical practice.
Patients are randomized to receive ticagrelor at a load-
ing dose of 180 mg followed by 90 mg bid or clopidogrel
at a loading dose of 300 mg, with provision for an ad-
ditional 300 mg in patients undergoing PCI, followed by
75 mg qd for up to 12 months. Patients already receiv-
ing clopidogrel at study entry are to receive a ticagrelor
loading dose or matching placebo, followed by the daily
regimen of either ticagrelor or clopidogrel. All patients
are to receive aspirin (75–100 mg/day). The primary ef-
ﬁcacy outcome is the composite endpoint of death from
vascular causes, myocardial infarction, or stroke. The pri-
mary safety outcome is PLATO-deﬁned and -adjudicated
major bleeding; the criteria used in PLATO were iden-
tiﬁed as constituting the most appropriate and clinically
meaningful assessment of bleeding complications associ-
ated with chronic therapy and are based on those used
in CURE (Table 9). Efﬁcacy and safety outcomes are to be
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assessed both overall and separately in patients with non-
ST-elevation ACS and patients with ST-elevation ACS,
and bleeding outcomes are to be assessed in relation to
timing of PCI and CABG. A program for assessing the oc-
currence of arrhythmic events in which a subpopulation
of patients underwent Holter monitoring for 7 days after
randomization (n = 2900) and again at 1 month (n =
2000) was completed in November 2007.
Study recruitment for PLATO ended in July 2008, with
enrollment of over 18,000 patients.
Conclusion
Ticagrelor, a CPTP agent, is the ﬁrst reversibly bind-
ing oral P2Y12 receptor antagonist. It produces plasma
concentration-dependent IPA that is rapid in onset and
greater in magnitude and less variable than that observed
with clopidogrel. The pharmacologic and clinical proﬁles
of this agent suggest that it may be capable of provid-
ing a high and consistent level of antithrombotic pro-
tection without a proportional increase in bleeding risk
and will likely offer more rapid offset of effect than do
current thienopyridine P2Y12 inhibitors. These charac-
teristics may improve the overall efﬁcacy of antiplatelet
therapy and facilitate management of ACS patients, in-
cluding those who will or may require surgical interven-
tion and thus would be at increased bleeding risk. Addi-
tionally, ticagrelor shows a similar safety and tolerability
proﬁle to clopidogrel in phase II trials and thus may pro-
vide a safe alternative to current therapy. The PLATO trial
will provide information on safety and efﬁcacy of tica-
grelor in a broad spectrum of ACS patients.
Acknowledgments
Editorial support was provided by BioScience Communi-
cations, funded by AstraZeneca.
Conﬂict of Interest
S. Husted has received speaker fees from AstraZeneca and
research grant support from AstraZeneca, Bayer, Bristol-
Myers Squibb and Sanoﬁ-Aventis. J.J.J. van Giezen is an
employee of AstraZeneca.
References
1. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of
clopidogrel to aspirin and ﬁbrinolytic therapy for
myocardial infarction with ST-segment elevation. NE n g lJ
Med 2005;352:1179–1189.
2. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G,
Fox KK. Clopidogrel in unstable angina to prevent
recurrent events trial investigators. Effects of clopidogrel
in addition to aspirin in patients with acute coronary
syndromes without ST-segment elevation. N Engl J Med
2001;345:494–502.
3. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA
2007 guidelines for the management of patients with
unstable angina/non-ST-elevation myocardial infarction.
Circulation 2007;116:803–877.
4. Bassand JP, Hamm CW, Ardissino D, et al., for the Task
Force for the Diagnosis and Treatment of
Non-ST-Segment Elevation Acute Coronary Syndromes
of European Society of Cardiology. Guidelines for the
diagnosis and treatment of non-ST-segment elevation
acute coronary syndromes. Eur Heart J
2007;28:1598–1660.
5. Savi P, Combalbert J, Gaich C, Rouchon MC, Maffrand
JP, Berger Y, Herbert JM. The antiaggregation activity of
clopidogrel is due to a metabolic activation by the hepatic
cytochrome P450-1A. Thromb Haemost 1994;72:313–317.
6. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of
hepatic cytochrome P450 3A4 metabolic activity to the
phenomenon of clopidogrel resistance. Circulation
2004;109:166–171.
7. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al.
Contribution of gene sequence variations of the hepatic
cytochrome P450 3A4 enzyme to variability in individual
responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol
2006;26:1895–1900.
8. Farid NA, Payne CD, Small DS, et al. Cytochrome P450
3A inhibition by ketoconazole affects prasugrel and
clopidogrel pharmacokinetics and pharmacodynamics
differently. Clin Pharmacol Ther 2007;81:735–741.
9. Gurbel PA, Bliden KP. Durability of platelet inhibition by
clopidogrel. Am J Cardiol 2003;91:1123–1125.
10. M¨ uller I, Besta F, Schulz C, Massberg S, Sch¨ onig A,
Gawaz M. Prevalence of clopidogrel non-responders
among patients with stable angina pectoris scheduled for
elective coronary stent placement. Thromb Haemost
2003;89:783–787.
11. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI,
Bhatt DL, Topol EJ. Variability in platelet responsiveness
to clopidogrel among 544 individuals. JA mC o l lC a r d i o l
2005;45:246–251.
12. Heptinstall S. Variable therapeutic effectiveness of
clopidogrel in acute coronary syndromes. J Thromb
Haemost 2006;4:539–541.
13. Geisler T, Langer H, Wydymus M, et al. Low response to
clopidogrel is associated with cardiovascular outcome
after coronary stent implantation. Eur Heart J
2006;27:2420–2425.
14. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F,
Macaya C, Bass TA, Costa MA. Variability in individual
responsiveness to clopidogrel: Clinical implications,
management, and future perspectives. JA mC o l lC a r d i o l
2007;49:1505–1516.
15. Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to
thienopyridines: Clinical detection of coronary stent
272 Cardiovascular Therapeutics 27 (2009) 259–274 c   2009 The Authors. Journal Compilation c   2009 Blackwell Publishing LtdS. Husted and J.J.J. van Giezen Ticagrelor
thrombosis by monitoring of vasodilator-stimulated
phosphoprotein phosphorylation. Cathet Cardiovasc
Intervent 2003;59:295–302.
16. Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM.
Clopidogrel for coronary stenting: Response variability,
drug resistance, and the effect of pretreatment platelet
reactivity. Circulation 2003;107:2908–2913.
17. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel
resistance is associated with increased risk of recurrent
atherothrombotic events in patients with acute
myocardial infarction. Circulation 2004;109:
3171–3175.
18. Ajzenberg N, Aubry P, Huisse MG, et al. Enhanced
shear-induced platelet aggregation in patients who
experience subacute stent thrombosis. A case-control
study. JA mC o l lC a r d i o l2005;45:1753–1756.
19. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR,
Tantry US. The relation of dosing to clopidogrel
responsiveness and the incidence of high post-treatment
platelet aggregation in patients undergoing coronary
stenting. JA mC o l lC a r d i o l2005;45:1392–1396.
20. Cuisset T, Frere C, Quilici J, et al. Beneﬁt of a 600-mg
loading dose of clopidogrel on platelet reactivity and
clinical outcomes in patients with non-ST-segment
elevation acute coronary syndrome undergoing coronary
stenting. JA mC o l lC a r d i o l2006;48:1339–1345.
21. Cuisset T, Frere C, Quilici J, et al. High post-treatment
platelet reactivity identiﬁed low-responders to dual
antiplatelet therapy at increased risk of recurrent
cardiovascular events after stenting for acute coronary
syndrome. J Thromb Haemost 2006;4:542–549.
22. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of
the degree of peri-interventional platelet inhibition after
loading with clopidogrel on early clinical outcome of
elective coronary stent placement. J Am Coll Cardiol
2006;48:1742–1750.
23. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel
drug response in patients undergoing percutaneous
coronary intervention. The role of dual drug resistance.
JA mC o l lC a r d i o l2006;47:27–33.
24. Bliden KP, DiChiara J, Tantry US, et al. Increased risk in
patients with high platelet aggregation receiving chronic
clopidogrel therapy undergoing percutaneous coronary
intervention. Is the current antiplatelet therapy
adequate? J Am Coll Cardiol 2007;49:657–666.
25. Buonamici P, Marcucci R, Migliorini A, et al. Impact of
platelet reactivity after clopidogrel administration on
drug-eluting stent thrombosis. JA mC o l lC a r d i o l
2007;49:2312–2317.
26. Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H. The
in vivo pharmacological proﬁle of CS-747, a novel
antiplatelet agent with platelet ADP receptor antagonist
properties. Br J Pharmacol 2000;129:1439–1446.
27. Jakubowski JA, Matsushima N, Asai F, et al. A multiple
dose study of prasugrel (CS-747), a novel thienopyridine
P2Y12 inhibitor, compared with clopidogrel in healthy
humans. Br J Clin Pharmacol 2006;63:421–430.
28. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel
achieves greater inhibition of platelet aggregation and a
lower rate of non-responders compared with clopidogrel
in aspirin-treated patients with stable coronary artery
disease. Eur Heart J 2006;27:1166–1173.
29. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel
versus clopidogrel in patients with acute coronary
syndromes. N Engl J Med 2007;357:2001–2015.
30. van Giezen JJJ, Humphries RG. Preclinical and clinical
studies with selective reversible direct P2Y12 antagonists.
Semin Thromb Hemost 2005;31:195–204.
31. Springthorpe B, Bailey A, Barton P, et al. From ATP to
AZD6140: The discovery of an orally active reversible
P2Y12 receptor antagonist for the prevention of
thrombosis. Bioorg Med Chem Lett 2007;17:6013–6018.
32. van Giezen JJJ, Berntsson P, Wissing B-M. Direct oral
P2Y12 receptor antagonist AZD6140 potently and
reversibly binds to the rh-P2Y12 receptor expressed on
CHO-K1 cells. Arterioscler Thromb Vasc Biol 2008;28:e-72
[Abstract P207].
33. Patil SBG, Norman KE, Robins SJ, Crosdale DJ, Nylander
S, Francis SE, Storey RF. Inhibition of thrombosis by
AZD6140 via selective blockade of the P2Y12 receptor in a
murine laser-injury model. J Thromb Haemost
2007;5:Abstract P-W-632.
34. Nilsson L, van Giezen JJJ, Greasley PJ. Evidence for
distinct ligand binding sites on recombinant P2Y12
receptors. Circulation 2006;114(Suppl II):II-248 [Abstract
1313].
35. van Giezen JJJ, Nilsson L. AZD6140 binds to the rh-P2Y12
receptor expressed on CHO-K1 cells at a site distinct from
the ADP binding site but antagonizes ADP-induced
signaling. Arterioscler Thromb Vasc Biol 2008;28:e-104
[Abstract P393].
36. van Giezen JJJ. Optimizing platelet inhibition. Eur Heart J
Suppl 2008;10(Suppl D):D23–D29.
37. van Giezen JJJ, Berntsson P. AZD6140 displays over
100-fold higher afﬁnity for the P2Y12 receptor vs
AZ11702105, a compound indistinguishable from the
active metabolite of prasugrel, and is a more potent
inhibitor of ADP-induced platelet aggregation. Arterioscler
Thromb Vasc Biol 2008;28:e-139–e-140
[Abstract P584].
38. van Giezen JJJ, Zachrisson H, Bj¨ orkman JA. Reduced
bleeding time prolongation for the reversible P2Y12
antagonist AZD6140 compared with clopidogrel and
AZ11703072, a chemical compound indistinguishable
from prasugrel, in both a rat and a dog model of
combined thrombosis and hemostasis. Arterioscler Thromb
Vasc Biol 2008;28:e-140 [Abstract P585].
39. Wihlborg A-K, Wang L, Braun O ¨ O, Eyjolfsson A,
Gustafsson R, Gudbjartsson T, Erlinge D. ADP receptor
P2Y12 is expressed in vascular smooth muscle cells and
Cardiovascular Therapeutics 27 (2009) 259–274 c   2009 The Authors. Journal Compilation c   2009 Blackwell Publishing Ltd 273Ticagrelor S. Husted and J.J.J. van Giezen
stimulates contraction in human blood vessels. Arterioscler
Thromb Vasc Biol 2004;24:1810–1815.
40. Svensson H, Erlinge D. The reversible oral P2Y12
antagonist AZD6140 inhibits ADP-induced contractions in
mouse aorta, in addition to established inhibitory effects
on platelet aggregation. Arterioscler Thromb Vasc Biol
2007;27:e-136 [Abstract P564].
41. Wang K, Zhou X, Zhou Z, et al. Blockade of the platelet
P2Y12 receptor by AR-C69931MX sustains coronary
artery recanalization and improves the myocardial tissue
perfusion in a canine thrombosis model. Arterioscler
Thromb Vasc Biol 2003;23:357–362.
42. Wang K, Zhou X, Huang Y, Khalil M, Wiktor D, Peng Y,
Penn MS. Adjunctive infusion of AZD6140, but not
clopidogrel, with t-PA enables sustained coronary artery
recanalization with recovery of myocardium perfusion in
a canine model of myocardial infarction. J Am Coll Cardiol
2009;53(Suppl A):A306–A307 [Abstract 1014–133].
43. Bj¨ orkman JA, Kirk I, van Giezen JJJ. AZD6140 inhibits
adenosine uptake into erythrocytes and enhances
coronary blood ﬂow after local ischemia or intracoronary
adenosine infusion. Circulation 2007;116(Suppl):II-28
[Abstract 245].
44. Butler K, Teng R. AZD6140, the ﬁrst reversible oral
platelet P2Y12 receptor antagonist, exhibits linear
pharmacokinetics following multiple doses in healthy
subjects, with greater and less variable inhibition of
platelet aggregation compared with clopidogrel. Can J Clin
Pharmacol 2008;15:e684–e685 [Abstract 562].
45. Butler K, Oliver S, Teng R. A mass balance study of major
excretory routes and metabolic proﬁle following an oral
[14C] dose of AZD6140, the ﬁrst reversible oral platelet
P2Y12 receptor antagonist, in healthy male subjects.
Presented at the 15th North American Regional Meeting
of the International Society for the Study of Xenobiotics,
October 12–16, 2008; San Diego, CA.
46. Peters G, Robbie G. Single dose pharmacokinetics and
pharmacodynamics of AZD6140. Haematologica
2004;89(Suppl 7):14–15.
47. Teng R, Butler K. AZD6140, the ﬁrst reversible oral
platelet P2Y12 receptor antagonist, has linear
pharmacokinetics and provides near complete inhibition
of platelet aggregation, with reversibility of effect, in
healthy subjects. Can J Clin Pharmacol 2008;15:e426
[Abstract 9].
48. Peters GR, Butler KA, Winter HR. Multiple-dose
pharmacokinetics (PK) and pharmacodynamics (PD) of
the oral reversible, orally active ADP receptor antagonist
AZD6140. Eur Heart J 2006;27(Suppl 1):P4556.
49. Butler K, Winter H, Mitchell P, Fox JC. Pharmacokinetics
and pharmacodynamics of AZD6140, the ﬁrst reversible
oral P2Y12 receptor antagonist, administered with aspirin.
J Clin Pharmacol 2007;47:Abstract 92.
50. Husted S, Emanuelsson H, Heptinstall S, Sandset PM,
Wickens M, Peters G. Pharmacodynamics,
pharmacokinetics, and safety of the oral reversible P2Y12
antagonist AZD6140 with aspirin in patients with
atherosclerosis: A double-blind comparison to clopidogrel
with aspirin. Eur Heart J 2006;27:1038–1047.
51. Cannon CP, Husted S, Harrington RA, et al., for the
DISPERSE-2 Investigators. Safety, tolerability, and initial
efﬁcacy of AZD6140, the ﬁrst reversible oral adenosine
diphosphate receptor antagonist, compared with
clopidogrel, in patients with non-ST-segment elevation
acute coronary syndrome: Primary results of the
DISPERSE-2 trial. JA mC o l lC a r d i o l2007;50:1844–1851.
Correction in JA mC o l lC a r d i o l2007;50:2196.
52. Storey RF, Husted S, Harrington RA, et al. Inhibition of
platelet aggregation by AZD6140, a reversible oral P2Y12
receptor antagonist, compared with clopidogrel in
patients with acute coronary syndromes. JA mC o l lC a r d i o l
2007;50:1852–1856.
53. James S, ˚ Akerblom A, Cannon C, et al. Comparison of
ticagrelor, the ﬁrst reversible oral P2Y12 receptor
antagonist, with clopidogrel in patients with acute
coronary syndromes: Rationale, design, and baseline
characteristics of the PLATelet inhibition and patient
Outcomes (PLATO) trial. Am Heart J 2009;157:599–605.
274 Cardiovascular Therapeutics 27 (2009) 259–274 c   2009 The Authors. Journal Compilation c   2009 Blackwell Publishing Ltd